TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

AACR 2017 | Poster 2448/5 – Deep exome sequencing reveals recurrent somatic mutations in Classical Hodgkin Lymphoma

By Terri Penfold

Share:

Apr 7, 2017


On Monday 3rd April during this year’s American Association for Cancer Research (AACR) annual meeting, a poster (2448 / 5) by Felicia Gomez, from Washington University, St. Louis, MO, et al. titled “Deep exome sequencing reveals recurrent somatic mutations in Hodgkin's Lymphoma” was presented.

The group hypothesized that recurrent somatic mutations can be recognized in Hodgkin Reed-Sternberg (HRS) cells, taken from biopsies of bulk Hodgkin Lymphoma (HL), using ultra-deep exome sequencing.

Key Highlights:

  • In total, using 63 samples from 31 patients, 7.04x1012 bases were sequenced; 1.10x1011 average bases per sample
  • Mean depth of coverage achieved in both tumor and normal samples is >1,000x; tumor coverage range = 50–17,498; normal coverage range = 50–22,837
  • Mutations identified in 31/32 patients
  • The most currently mutated genes = SOCS1 (11 mutations), and TNFAIP3 and IGLL5 (7 mutations each)
  • Mutations in TNFAIP3 were frameshift deletions, nonsense, and splice site mutations (all potentially truncating)
  • Identified other mutations known to be mutated in cHL = B2M, STAT6, ITPK, GNA13, BCL7A, and CREBBP

The poster concluded by stating that recurrent mutations in cHL can be identified using ultra-deep sequencing of bulk tumor tissue. The group identified previously unreported mutations which require validation, as well as known mutations. This data improves our understanding of the pathogenesis of cHL.

References